Long-term results of primary adenocarcinoma of the urinary bladder: A report on 192 patients

Zaghloul, Mohamed S.; Nouh, Mohamed A.; Nazmy, Mohamed; Ramzy, Samy; zaghloul, Ashraf; Sedira, Mohamed Abou; Khalil, Ehab

doi:10.1016/j.urolonc.2005.05.027

Cited by 110 publications

(103 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Interestingly, recent genomic data have described a basal/squamous-like molecular subtype that has squamoid morphology and immunophenotype and is associated with poor survival and poor response to systemic therapy [69,70]. Glandular neoplasms constitute the second most common form of divergent differentiation, seen in up to 18% of invasive tumours and defined by the presence of gland formation [71][72][73]. These tumours commonly have enteric features and, in isolation, can be easily confused with colonic adenocarcinoma.…”

Section: Invasive Urothelial Carcinoma With Divergent Differentiationmentioning

confidence: 99%

The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part B: Prostate and Bladder Tumours

et al. 2016

View full text Add to dashboard Cite

It has been 12 yr since the publication of the last World Health Organization (WHO) classification of tumours of the prostate and bladder. During this time, significant new knowledge has been generated about the pathology and genetics of these tumours. Intraductal carcinoma of the prostate is a newly recognized entity in the 2016 WHO classification. In most cases, it represents intraductal spread of aggressive prostatic carcinoma and should be separated from high-grade prostatic intraepithelial neoplasia. New acinar adenocarcinoma variants are microcystic adenocarcinoma and pleomorphic giant cell adenocarcinoma. Modifications to the Gleason grading system are incorporated into the 2016 WHO section on grading of prostate cancer, and it is recommended that the percentage of pattern 4 should be reported for Gleason score 7. The new WHO classification further recommends the recently developed prostate cancer grade grouping with five grade groups. For bladder cancer, the 2016 WHO classification continues to recommend the 1997 International Society of Urological Pathology grading classification. Newly described or better defined noninvasive urothelial lesions include urothelial dysplasia and urothelial proliferation of uncertain malignant potential, which is frequently identified in patients with a prior history of urothelial carcinoma. Invasive urothelial carcinoma with divergent differentiation refers to tumours with some percentage of "usual type" urothelial carcinoma combined with other morphologies. Pathologists should mention the percentage of divergent histologies in the pathology report. PATIENT SUMMARY Intraductal carcinoma of the prostate is a newly recognized entity in the 2016 World Health Organization classification. Better defined noninvasive urothelial lesions include urothelial dysplasia and urothelial proliferation of uncertain malignant potential. v a i l a b l e a t w w w . s c i e n c e d i r e c t . c o m j AbstractIt has been 12 yr since the publication of the last World Health Organization (WHO) classification of tumours of the prostate and bladder. During this time, significant new knowledge has been generated about the pathology and genetics of these tumours.

show abstract

Section: Invasive Urothelial Carcinoma With Divergent Differentiationmentioning

confidence: 99%

The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part B: Prostate and Bladder Tumours

et al. 2016

View full text Add to dashboard Cite

show abstract

“…This big difference in radiation volume led to the discrepancy in the reported late GIT and therefore the hesitancy of the oncology community to re-investigate the value of post-operative radiotherapy after radical cystectomy. Obviously, Abd El-Moneim et al [1] emphasized the previously reported mild complication rates [2][3][4] and concluded that pre-and post-operative radiotherapy was tolerable and safe. This report though being the first comparing these 2 modalities of radiation, yet it used a conventional 2D technique with 3 fields arrangement.…”

mentioning

confidence: 99%

“…In another retrospective study, a total of 12% of the patients who received PORT experienced chronic intestinal complications of different grades compared with 8% in the cystectomy alone group. There were four patients in each group (5.8% and 3.3%, respectively) that needed surgery for intestinal late complications [4] . On the other hand, much higher late GIT complications were reported by Reseinger et al [5] .…”

mentioning

confidence: 99%

Re-evaluation of the value of adjunctive modern radiotherapy in muscle-invasive bladder cancer

Zaghloul

2012

JST

View full text Add to dashboard Cite

A controlled prospective randomized study was recently published; comparing pre-and post-operative radiotherapy in bladder cancer patients [1] . This study was the first to compare these radical cystectomy adjunctive radiation methods. For decades left, both pre-and post-operative radiotherapy in bladder cancer had negative image for genitourinary oncologists. This unsatisfactory image was either due to insignificant improvement in the published survival rates or due to the fear of high and unacceptable late complications [2] . Abd El-Moneim et al. [1] achieved 5-year overall survival of 51% as 89% of their patients belonged to the clinical categories T3 and T4. They showed clearly that there was no difference between the 2 randomized groups; in overall survival, disease-free survival, local control and distant metastasis-free rates. It was clear from their results that both immediate postoperative complications and late serious gasterointestinal (GIT) sequalae were similar in both groups and of minimal amplitude. Late bowel complications were reported to be 4.5% in the post-operative setting and 2% in the pre-operative setting this was nearly similar to the percentages reported previously by Zaghloul et al. [3] who reported 4% and 5% grade 3+4 late bowel toxicity in conventional and hyper fractionated postoperative radiotherapy groups. In another retrospective study, a total of 12% of the patients who received PORT experienced chronic intestinal complications of different grades compared with 8% in the cystectomy alone group. There were four patients in each group (5.8% and 3.3%, respectively) that needed surgery for intestinal late complications [4] . On the other hand, much higher late GIT complications were reported by Reseinger et al. [5] . They experienced 37% late GIT complications with 22

show abstract

“…[1][2][3] In some cases, primary adenocarcinoma has been associated with bladder exstrophy. [4][5][6] Patients with primary urinary bladder adenocarcinoma tend to present at a higher stage than those with urothelial carcinoma, although in some circumstances survival appears similar to or better than that of urothelial carcinoma. 6,7 Histologically, tumors tend to demonstrate enteric morphology, closely resembling colonic adenocarcinoma.…”

mentioning

confidence: 99%

“…9,10 Radical surgery is the definitive treatment, although postoperative radiotherapy has been reported to enhance survival. 4,5,11 Nonetheless, there is a need for better understanding of the pathogenesis of urinary bladder adenocarcinoma to guide more effective therapy.…”

mentioning

confidence: 99%

EGFR alterations and EML4-ALK rearrangement in primary adenocarcinoma of the urinary bladder

et al. 2014

View full text Add to dashboard Cite

The identification of mutations in epidermal growth factor receptor (EGFR) and translocations involving anaplastic lymphoma kinase (ALK) in lung adenocarcinoma has drastically changed understanding of the disease and led to the development of targeted therapies. Adenocarcinoma of the urinary bladder is rare and poorly understood at the molecular level. We undertook this study to determine whether EGFR mutations, increases in EGFR copy number, or ALK translocations are present in these tumors. Twenty-eight cases of primary bladder adenocarcinoma were analyzed. For EGFR mutational analysis, PCR-amplified products were analyzed on the Q24 Pyrosequencer with Qiagen EGFR Pyro Kits. All cases were analyzed via fluorescence in situ hybridization (FISH) using Vysis ALK Break Apart FISH Probes for detection of ALK chromosomal translocation and Vysis Dual Color Probes to assess for increased gene copy number of EGFR. None of the 28 cases examined showed mutational events in EGFR or ALK rearrangements. EGFR polysomy was seen in 10 out of 28 (36%) cases. No correlation with EGFR polysomy was seen in the tumors with respect to age, histologic subtypes, pathologic stage, or lymph node metastasis. In summary, EGFR mutations and ALK rearrangements do not appear to be involved in the development of primary adenocarcinoma of the urinary bladder. A subgroup of cases (36%), however, demonstrated increased gene copy number of EGFR by FISH.

show abstract

Long-term results of primary adenocarcinoma of the urinary bladder: A report on 192 patients

Cited by 110 publications

References 25 publications

The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part B: Prostate and Bladder Tumours

The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part B: Prostate and Bladder Tumours

Re-evaluation of the value of adjunctive modern radiotherapy in muscle-invasive bladder cancer

EGFR alterations and EML4-ALK rearrangement in primary adenocarcinoma of the urinary bladder

Contact Info

Product

Resources

About